600513 联环药业
已收盘 08-17 15:00:00
资讯
新帖
简况
每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信
证券之星 · 08-16 01:39
每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信
股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》
证券之星 · 08-12
股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》
联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%
证券之星 · 08-11
联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%
股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》
证券之星 · 08-10
股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》
每周股票复盘：联环药业（600513）两款产品拟中选集采
证券之星 · 08-09
每周股票复盘：联环药业（600513）两款产品拟中选集采
联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%
证券之星 · 08-07
联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%
联环药业最新公告：获得乳果糖口服溶液药品注册证书
证券之星 · 08-07
联环药业最新公告：获得乳果糖口服溶液药品注册证书
联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购
智通财经 · 08-03
联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购
每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请
证券之星 · 08-02
每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请
异动快报：联环药业（600513）7月30日10点2分触及涨停板
证券之星 · 07-30
异动快报：联环药业（600513）7月30日10点2分触及涨停板
联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%
证券之星 · 07-27
联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%
联环药业(600513.SH)：化学原料药阿加曲班上市申请获批
智通财经 · 07-22
联环药业(600513.SH)：化学原料药阿加曲班上市申请获批
联环药业（600513）披露控股子公司获得《药品注册证书》，7月16日股价下跌9.76%
证券之星 · 07-16
联环药业（600513）披露控股子公司获得《药品注册证书》，7月16日股价下跌9.76%
联环药业(600513.SH)子公司获得达格列净二甲双胍缓释片药品注册证书
智通财经 · 07-16
联环药业(600513.SH)子公司获得达格列净二甲双胍缓释片药品注册证书
联环药业（600513）披露2026年半年度业绩预告，7月14日股价上涨4.58%
证券之星 · 07-14
联环药业（600513）披露2026年半年度业绩预告，7月14日股价上涨4.58%
联环药业（600513）披露股票交易异常波动的公告，7月13日股价上涨10.01%
证券之星 · 07-13
联环药业（600513）披露股票交易异常波动的公告，7月13日股价上涨10.01%
7月13日联环药业（600513）龙虎榜数据：机构净买入4707.05万元（3日），北向资金净卖出1843.73万元（3日）
证券之星 · 07-13
7月13日联环药业（600513）龙虎榜数据：机构净买入4707.05万元（3日），北向资金净卖出1843.73万元（3日）
联环药业获得实用新型专利授权：“一种小容量注射剂生产用浓配装置”
证券之星 · 07-11
联环药业获得实用新型专利授权：“一种小容量注射剂生产用浓配装置”
股市必读：联环药业（600513）7月7日收盘跌6.58%，主力净流出1422.4万元
证券之星 · 07-08
股市必读：联环药业（600513）7月7日收盘跌6.58%，主力净流出1422.4万元
每周股票复盘：联环药业（600513）每股派息0.07元
证券之星 · 07-05
每周股票复盘：联环药业（600513）每股派息0.07元
加载更多
公司概况
公司名称：
江苏联环药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-19
主营业务：
江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。
发行价格：
7.88
{"stockData":{"symbol":"600513","market":"SH","secType":"STK","nameCN":"联环药业","latestPrice":18.52,"timestamp":1786950000000,"preClose":17.62,"halted":0,"volume":34123068,"delay":0,"changeRate":0.0511,"floatShares":285000000,"shares":285000000,"eps":-0.4028,"marketStatus":"已收盘","change":0.9,"latestTime":"08-17 15:00:00","open":17.9,"high":18.69,"low":17.05,"amount":615000000,"amplitude":0.0931,"askPrice":18.53,"askSize":258,"bidPrice":18.52,"bidSize":1259,"shortable":0,"etf":0,"ttmEps":-0.4028,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787016600000},"marketStatusCode":5,"adr":0,"adjPreClose":17.62,"symbolType":"stock","openAndCloseTimeList":[[1786930200000,1786937400000],[1786942800000,1786950000000]],"highLimit":19.38,"lowLimit":15.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":285456270,"isCdr":false,"pbRate":4.13,"roa":"--","roe":"0.5%","epsLYR":-0.34,"committee":0.128682,"marketValue":5287000000,"turnoverRate":0.1195,"status":0,"floatMarketCap":5287000000},"requestUrl":"/m/hq/s/600513","defaultTab":"news","newsList":[{"id":"2659759031","title":"每周股票复盘：联环药业（600513）控股子公司拟申请2.715亿元授信","url":"https://stock-news.laohu8.com/highlight/detail?id=2659759031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659759031?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:39","pubTimestamp":1786815548,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，联环药业报收于17.62元，较上周的18.07元下跌2.49%。本周，联环药业8月10日盘中最高价报18.78元。本周关注点公司公告汇总：全资子公司控股的四川龙一医药拟申请不超过2.715亿元综合授信。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658120779","title":"股市必读：联环药业新发布《联环药业第九届董事会第二十六次临时会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658120779","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658120779?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:45","pubTimestamp":1786470315,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，联环药业报收于17.4元，下跌1.53%，换手率8.12%，成交量23.19万手，成交额4.09亿元。当日关注点交易信息汇总：8月11日主力资金净流出537.99万元，占总成交额1.31%。公司公告汇总：控股子公司拟向关联方借款1000万元，年利率2.5%（含税），期限不超过3个月，由自然人股东以股权按比例提供担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658916245","title":"联环药业（600513）披露控股子公司向关联方借款暨关联交易公告，8月11日股价下跌1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916245","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916245?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:16","pubTimestamp":1786457786,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，联环药业报收于17.4元，较前一交易日下跌1.53%，最新总市值为49.67亿元。近日，联环药业发布《关于控股子公司向关联方借款暨关联交易的公告》。公告显示，公司控股子公司联环（南京）医疗科技有限公司因日常经营周转需要，拟向关联方江苏联环健康产业管理发展有限公司借款人民币1,000万元，借款期限不超过3个月，年利率为2.5%（含税），到期一次性还本付息。本次交易构成关联交易，但不构成重大资产重组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670042","title":"股市必读：联环药业新发布《联环药业关于公司获得《药品注册证书》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670042","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670042?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:00","pubTimestamp":1786298450,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，上涨2.03%，换手率11.76%，成交量33.57万手，成交额6.02亿元。当日关注点交易信息汇总：8月7日主力资金净流入517.74万元，占总成交额0.86%。公司公告汇总：联环药业获乳果糖口服溶液《药品注册证书》，按化学药品4类申报，视同通过仿制药一致性评价。该药品适用于慢性或习惯性便秘、肝性脑病的治疗和预防。2025年全国二级以上医院该药品销售额达5.63亿元。公司针对该药品的研发投入约529.70万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967580","title":"每周股票复盘：联环药业（600513）两款产品拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967580","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658967580?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:27","pubTimestamp":1786213630,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，较上周的17.32元上涨4.33%。本周，联环药业8月7日盘中最高价报18.3元。拟中选产品采购周期至2029年12月31日，具体采购协议签署方式由各省确定。联环药业近日取得国家药监局核准签发的乳果糖口服溶液《药品注册证书》，按化学药品4类申报，视同通过仿制药质量和疗效一致性评价。2025年全国二级以上医院该药品销售额达5.63亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657441686","title":"联环药业（600513）披露公司获得《药品注册证书》，8月7日股价上涨2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657441686","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657441686?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:24","pubTimestamp":1786112684,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，联环药业报收于18.07元，较前一交易日上涨2.03%，最新总市值为51.58亿元。该股当日开盘17.4元，最高18.3元，最低17.3元，成交额达6.02亿元，换手率为11.76%。近日，江苏联环药业股份有限公司收到国家药品监督管理局核准签发的乳果糖口服溶液《药品注册证书》，该药品按化学药品4类申报，视同通过仿制药质量和疗效一致性评价。2025年全国二级以上医院该药品销售额达5.63亿元。公司针对该药品的研发投入约529.70万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657485616","title":"联环药业最新公告：获得乳果糖口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657485616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657485616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092683,"startTime":"0","endTime":"0","summary":"联环药业(600513.SH)公告称，公司近日收到国家药监局核准签发的乳果糖口服溶液(200ml:133.4g/15ml:10g)《药品注册证书》，该药品适用于慢性或习惯性便秘及肝性脑病。本次获批视同通过仿制药质量和疗效一致性评价，进一步丰富了公司产品线，但预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321059","title":"联环药业(600513.SH)：布美他尼注射剂等药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321059","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656321059?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:33","pubTimestamp":1785746004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业(600513.SH)发布公告，公司及控股子公司新乡市常乐制药有限责任公司参加了由国家组织药品联合采购办公室组织开展的第十二批全国药品集中采购投标工作。根据联采办发布的《第12批国家组织药品集中带量采购拟中选结果公示》，公司及控股子公司常乐制药药品：美阿沙坦口服常释剂型、布美他尼注射剂、维生素B6注射剂中选本次集中采购。本次药品集中采购是联采办组织的第十二批国家药品集中采购，在执行上要求医疗机构优先使用集中采购中选品种，并确保完成约定采购量。公司及子公司后续签订采购合同并实施后，将有利于上述产品快速打开国内销售市场，提高市场占有率，提升公司的品牌影响力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656161723","title":"每周股票复盘：联环药业（600513）创新药LH-1801提交Pre-NDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2656161723","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656161723?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:15","pubTimestamp":1785608113,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，联环药业报收于17.32元，较上周的15.42元上涨12.32%。本周，联环药业7月31日盘中最高价报17.55元。本周共计1次涨停收盘，无跌停收盘情况。本周关注点来自公司公告汇总：创新药LH-1801已完成与达格列净的头对头Ⅲ期临床试验，目前已提交Pre-NDA沟通交流申请。爱普列特原料库存管理稳定，产品上市二十余年持续增长，2025年销售额同比增长6.2%，已纳入多项诊疗指南。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","600513","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655551849","title":"异动快报：联环药业（600513）7月30日10点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2655551849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655551849?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:11","pubTimestamp":1785377461,"startTime":"0","endTime":"0","summary":"证券之星7月30日盘中消息，10点2分联环药业（600513）触及涨停板。其所属行业化学制药目前上涨。领涨股为海南海药。该股为化妆品，江苏国企改革，医药概念热股，当日化妆品概念上涨1.26%，江苏国企改革概念上涨0.89%，医药概念上涨0.84%。7月29日的资金流向数据方面，主力资金净流出1804.13万元，占总成交额5.37%，游资资金净流入782.53万元，占总成交额2.33%，散户资金净流入1021.6万元，占总成交额3.04%。近5日资金流向一览见下表：联环药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000009912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045732","title":"联环药业（600513）披露投资者关系活动记录表，7月27日股价上涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654045732?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:15","pubTimestamp":1785161759,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，联环药业报收于15.94元，较前一交易日上涨3.37%，最新总市值为45.5亿元。该股当日开盘15.0元，最高16.08元，最低15.0元，成交额达3.3亿元，换手率为7.36%。近日，联环药业发布投资者关系活动记录表。公告显示，公司于2026年7月24日举行投资者关系活动，就爱普列特原料库存管理、销售增长及市场前景作出说明，该产品上市二十余年持续增长，2025年销售额同比增长6.2%，已纳入多项诊疗指南。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758153","title":"联环药业(600513.SH)：化学原料药阿加曲班上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758153","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653758153?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:20","pubTimestamp":1784708443,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业(600513.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于原料药阿加曲班的《化学原料药上市申请批准通知书》。阿加曲班是一种直接凝血酶抑制剂，可逆地与凝血酶活性位点结合，其注射剂适用于：(1)发病48小时内的缺血性脑梗死急性期病人的神经症状(运动麻痹)、日常活动(步行、起立、坐位保持、饮食)的改善;(2)对慢性动脉闭塞症(血栓闭塞性脉管炎、闭塞性动脉硬化症)患者的四肢溃疡，静息痛及冷感等的改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600513","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651436440","title":"联环药业（600513）披露控股子公司获得《药品注册证书》，7月16日股价下跌9.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651436440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651436440?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:12","pubTimestamp":1784211142,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，联环药业报收于17.28元，较前一交易日下跌9.76%，最新总市值为49.33亿元。该股当日开盘18.57元，最高19.0元，最低17.24元，成交额达7.91亿元，换手率为15.48%。近日，江苏联环药业股份有限公司控股子公司新乡市常乐制药有限责任公司收到国家药品监督管理局核准签发的达格列净二甲双胍缓释片《药品注册证书》。常乐制药对该药品的研发投入约为963.00万元。此次获批进一步丰富了公司产品线，但预计不会对公司近期经营业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651841222","title":"联环药业(600513.SH)子公司获得达格列净二甲双胍缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2651841222","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651841222?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:26","pubTimestamp":1784190394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业(600513.SH)发布公告，公司控股子公司新乡市常乐制药有限责任公司于近日收到国家药品监督管理局核准签发的关于达格列净二甲双胍缓释片(Ⅰ/Ⅱ/Ⅲ)的《药品注册证书》。达格列净二甲双胍缓释片(Ⅰ/Ⅱ/Ⅲ)配合饮食控制和运动，适用于正在接受达格列净和盐酸二甲双胍治疗的2型糖尿病成人患者改善血糖控制。该药品按照化学药品4类进行申报，视同通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联环药业(600513.SH)子公司获得达格列净二甲双胍缓释片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651010091","title":"联环药业（600513）披露2026年半年度业绩预告，7月14日股价上涨4.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651010091","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651010091?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:13","pubTimestamp":1784038398,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，联环药业报收于17.82元，较前一交易日上涨4.58%，最新总市值为50.87亿元。该股当日开盘17.03元，最高17.82元，最低16.51元，成交额达8.8亿元，换手率为17.76%。近日，江苏联环药业股份有限公司发布2026年半年度业绩预告，预计归属于上市公司股东的净利润为970.00万元至1,160.00万元，实现扭亏为盈，较上年同期增长4,972.84万元至5,162.84万元。扣除非经常性损益后的净利润预计为810.00万元至970.00万元，同比有所下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651689117","title":"联环药业（600513）披露股票交易异常波动的公告，7月13日股价上涨10.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651689117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651689117?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:06","pubTimestamp":1783951583,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，联环药业报收于17.04元，较前一交易日上涨10.01%，最新总市值为48.64亿元。该股当日开盘15.66元，最高17.04元，最低14.82元，成交额达6.75亿元，换手率为14.86%。近日，联环药业发布《股票交易异常波动的公告》。公告显示，公司股票于2026年7月10日、7月13日连续两个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。公司经自查并书面征询控股股东及实际控制人，确认目前生产经营正常，不存在应披露而未披露的重大事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300039833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651118658","title":"7月13日联环药业（600513）龙虎榜数据：机构净买入4707.05万元（3日），北向资金净卖出1843.73万元（3日）","url":"https://stock-news.laohu8.com/highlight/detail?id=2651118658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651118658?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:57","pubTimestamp":1783936651,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月13日公布的交易公开信息显示，联环药业因非S证券连续三个交易日内收盘价格涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月13日收盘，联环药业报收于17.04元，上涨10.01%，已连续涨停2天，换手率14.86%，成交量42.43万手，成交额6.75亿元。从龙虎榜公布的三日买卖数据来看，机构合计净买入4707.05万元，北向资金合计净卖出1843.73万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300027215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650329481","title":"联环药业获得实用新型专利授权：“一种小容量注射剂生产用浓配装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650329481","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650329481?lang=zh_cn&edition=full","pubTime":"2026-07-11 03:51","pubTimestamp":1783713077,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示联环药业新获得一项实用新型专利授权，专利名为“一种小容量注射剂生产用浓配装置”，专利申请号为CN202521567696.6，授权日为2026年6月26日。今年以来联环药业新获得专利授权17个，较去年同期增加了21.43%。通过天眼查大数据分析，江苏联环药业股份有限公司共对外投资了13家企业，参与招投标项目6126次；财产线索方面有商标信息85条，专利信息298条；此外企业还拥有行政许可647个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071100002319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934558","title":"股市必读：联环药业（600513）7月7日收盘跌6.58%，主力净流出1422.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934558","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649934558?lang=zh_cn&edition=full","pubTime":"2026-07-08 01:44","pubTimestamp":1783446251,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，联环药业报收于14.9元，下跌6.58%，换手率4.66%，成交量13.32万手，成交额2.03亿元。交易信息汇总：7月7日主力资金净流出1422.4万元，散户资金净流入1345.48万元。交易信息汇总股价提醒7月7日联环药业收盘报14.9元，跌6.58%，当日成交2.03亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800000989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649469443","title":"每周股票复盘：联环药业（600513）每股派息0.07元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649469443","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649469443?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:38","pubTimestamp":1783190290,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，联环药业报收于15.9元，较上周的14.23元上涨11.74%。本周，联环药业7月2日盘中最高价报16.39元。本周关注点公司公告汇总：联环药业2025年度每股派发现金红利0.070元（含税），股权登记日为2026年7月7日。出席会议股东所持表决权股份占公司总股本的43.0522%。联环药业关于调整公司各专门委员会委员的公告：2026年6月30日召开第九届董事会第二十五次临时会议，审议通过调整公司各专门委员会委员议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786976239778,"stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.1171},{"period":"6month","weight":-0.1179},{"period":"1year","weight":-0.2933},{"period":"ytd","weight":-0.0331}],"compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0379},{"period":"1year","weight":0.0711},{"period":"ytd","weight":-0.0105}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏联环药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42663人(较上一季度减少13.63%)","perCapita":"6690股","listingDate":"2003-03-19","address":"江苏省扬州市邗江区生物健康产业园健康一路9号","registeredCapital":"28545万元","survey":" 江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。","listedPrice":7.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联环药业,600513,联环药业股票,联环药业股票老虎,联环药业股票老虎国际,联环药业行情,联环药业股票行情,联环药业股价,联环药业股市,联环药业股票价格,联环药业股票交易,联环药业股票购买,联环药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}